Hims & Hers Stock Accelerates on ‘Incrementally Positive’ U.S. Push to Ease Peptide Restrictions
TipRanks (Thu, 16-Apr 12:10 PM ET)
Hims & Hers Stock Accelerates on ‘Incrementally Positive’ Push to Ease Peptide Restrictions
TipRanks (Thu, 16-Apr 12:10 PM ET)
Biggest stock movers Thursday: AEHR, ABT, HOOD, COIN, and more
Seeking Alpha News (Thu, 16-Apr 10:32 AM ET)
Why Is Hims & Hers Stock Soaring After FDA's Announcment?
Benzinga (Thu, 16-Apr 6:28 AM ET)
Hims & Hers Health (HIMS) Gets a Hold from Bank of America Securities
TipRanks (Thu, 16-Apr 5:57 AM ET)
Hims & Hers on track to extend gains as RFK Jr. seeks to loosen peptide regulations
Seeking Alpha News (Thu, 16-Apr 5:15 AM ET)
Biggest stock movers Thursday: HIMS, quantum computing stocks, and more
Seeking Alpha News (Thu, 16-Apr 5:01 AM ET)
Here's How Much $1000 Invested In Hims & Hers Health 5 Years Ago Would Be Worth Today
Benzinga (Wed, 15-Apr 6:02 PM ET)
Hims & Hers Stock (HIMS) Soars after RFK Jr. Signals Looser Rules on Peptide Treatments
TipRanks (Wed, 15-Apr 5:29 PM ET)
FDA sets up AdCom meeting to decide on lifting restrictions on certain peptides
Seeking Alpha News (Wed, 15-Apr 1:42 PM ET)
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Hims & Hers Health Class A trades on the NYSE stock market under the symbol HIMS.
As of April 16, 2026, HIMS stock price climbed to $26.50 with 39,965,156 million shares trading.
HIMS has a beta of 1.17, meaning it tends to be more sensitive to market movements. HIMS has a correlation of 0.03 to the broad based SPY ETF.
HIMS has a market cap of $6.04 billion. This is considered a Mid Cap stock.
Last quarter Hims & Hers Health Class A reported $618 million in Revenue and $.08 earnings per share. This fell short of revenue expectation by $-207,922 and exceeded earnings estimates by $.05.
In the last 3 years, HIMS traded as high as $72.98 and as low as $5.65.
The top ETF exchange traded funds that HIMS belongs to (by Net Assets): IJH, VTI, IWM, VB, VBK.
HIMS has underperformed the market in the last year with a return of -10.0%, while the SPY ETF gained +31.9%. In the last 3 month period, HIMS fell short of the market, returning -15.1%, while SPY returned +1.6%. However, in the most recent 2 weeks HIMS has outperformed the stock market by returning +33.6%, while SPY returned +7.1%.
HIMS support price is $22.84 and resistance is $25.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HIMS shares will trade within this expected range on the day.